LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases
Amanda E.D. Van Swearingen(Duke Cancer Institute), Carey K. Anders(Duke University), Rita Nanda(University of Chicago), Lisle M. Nabell(Memorial Sloan Kettering Cancer Center), Hyman B. Muss(University of North Carolina at Chapel Hill), Nirali M. Patel(University of North Carolina at Chapel Hill), Elizabeth Claire Dees(University of North Carolina at Chapel Hill), Heejoon Jo(University of North Carolina at Chapel Hill), C. Ryan Miller(University of North Carolina at Chapel Hill), Julie Gottlieb Fisher(Carolinas Medical Center), Paul Little(University of North Carolina at Chapel Hill), Lisa A. Carey(University of North Carolina at Chapel Hill), Joel S. Parker(University of North Carolina at Chapel Hill), Allison M. Deal(Memorial Sloan Kettering Cancer Center), D. Neil Hayes(University of North Carolina at Chapel Hill), Patrick M. Dillon(University of Virginia), Vandana G. Abramson(Vanderbilt University), J. Keith Smith(Merck & Co., Inc., Rahway, NJ, USA (United States)), Maria J. Sambade(University of North Carolina at Chapel Hill), Nikita Shah(Orlando Health), Timothy M. Zagar(University of North Carolina at Chapel Hill), Trevor A. Jolly(University of North Carolina at Chapel Hill), Marni B. Siegel(University of North Carolina at Chapel Hill), Alan P. Hoyle(University of North Carolina at Chapel Hill)
Cited by 48
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
|JAMA|2017|2.3k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k